Trius and General Market Commentary 6/5/13.. Answering critics and explaining market cap to price. Business basics as well.
Tag: ACAD
Trius Therapeutics: The Next Big Small-Cap Biotech Mover?
Normally, I write about biotech companies with near-term catalysts I feel offer traders good long based trade opportunities heading into these catalysts. Every so often, I find a small cap biotech where I feel a speculation investment is truly warranted.…
4 Top Small Cap Biotech Acquisition Targets
Today, I list small cap companies I believe are top acquisition targets for large pharma. I combine speculation, rumors and buzz I am hearing, and company financial position as a few factors for consideration. Buy-outs are hard to predict in…
Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billion
Today, we will take a detailed look into a company that has an imminent catalyst, a number of important Phase II and Phase III data releases throughout 2013, and a product pipeline with potential to tap into a $17B market.…
Valeant Acquires Obagi, Which Biotechs Are Next?
Yesterday, Obagi Medical Products (OMPI) was acquired by Valeant Pharmaceuticals (VRX) for $19.75 a share in an all cash deal. Last summer I covered in depth, acquisition rumors regarding Obagi. At the time, good private sources of mine confirmed that…
The Obesity Epidemic – EnteroMedics New Treatment Approach
Our focus turns to EnteroMedics (NASDAQ:ETRM), which offers a new treatment approach currently in Phase III clinical trials, designed to help morbidly obese people lose weight. EnteroMedics’ approach may be a better solution for people who see little or no…
Neptune’s Bounce Should Continue: $3 in range
Originally posted at www.biomedreports.com Updated by StockMatusow.com Twitter @BioMedReports @ScottMatusow Neptune Technologies & Bioressources announced they will hold a conference call on Thursday, January 17th at 4:30 EST. The reason given for the call will be to discuss the third…
BioLineRx: Big Catalyst Upcoming With Potential Multi Billion Dollar Schizophrenia Drug
BioLineRx’s (BLRX) engages in identifying, in-licensing, and developing therapeutic candidates. Its lead clinical therapeutic candidate under development is BL-1020, which is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients. BL-1020 is an orally available, first in…
Strong Small Cap Biopharma Catalyst Trades And Investments For Consideration
Trading biophama stocks before a catalyst event, if done correctly, can be a very profitable proposition. Some traders and investors who enjoy bringing more risk into play often times will hold through the actual catalyst event. While this does bring…
ArQule: A Strong Speculation BioPharma Poised For A Quick Move Up On Near Term Catalyst
ArQule (NASDAQ: ARQL) ArQule engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate Tivantinib (ARQ 197) is an inhibitor of the c-Met receptor tyrosine kinase, which is in Phase…
